FierceBiotechOriginal article
{"a":[{"_":"Xenon pauses phase 3 depression trials after psychosis events","$":{"href":"/biotech/xenon-pauses-phase-3-depression-trials-after-psychosis-events","hreflang":"en"}}]}
Phase 3negativeNegative
AI Analysis
Summary
Xenon has voluntarily paused enrollment in Phase 3 depression trials following reports of mostly mild to moderate psychosis adverse events. The pause reflects safety concerns that could impact the program's development timeline.
Clinical Trial Data
Phase
3
Outcome Details
Voluntary pause in enrollment due to reports of mostly mild or moderate psychosis adverse events
Importance:7/10
Sentiment:
-0.80
adverse eventspsychosisenrollment pausePhase 3depression
Read the original article
Published by FierceBiotech on September 18, 2026 5:33 AM